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Abstract
Background: House dust mite (HDM) allergens constitute the leading trigger for the symptoms of persistent
respiratory allergies (such as allergic rhinitis and asthma). However, the fluctuating, pernicious nature of the
symptoms has given rise to a perception that HDM-induced respiratory allergy is not a “real” disease.
Methods: In order to assess the self-reported disease profile and behaviour of adult patients with a self-reported
history of severe, poorly controlled, physician-diagnosed HDM respiratory allergy, we performed an observational,
international, multicentre survey in three European countries (France, Italy and Spain). Participants were included
in the survey if they passed a short Internet-based screening questionnaire. Following completion of a detailed
post-inclusion questionnaire, 28 fortnightly telephone interviews were used to gather extensive data on the
participants’ symptom prevalence and intensity, medical consultations, disease burden, quality of life, and
medication use from late May 2012 to early July 2013.
Results: Twenty-two thousand nine hundred ninety five individuals completed the Internet screening questionnaire
and 339 respondents (67 % female) met all the inclusion criteria. 313 of the 339 (92 %) completed the
post-inclusion questionnaire (n = 114 in Italy, 92 in France and 107 in Spain). The median time since the first
symptoms of HDM allergy was over 13 years in all three countries. The response rate for the fortnightly interviews
averaged 75 % (range: 29 to 97 %). The reported fortnightly prevalence of nasal and ocular symptoms peaked in
the autumn (September to November) and spring (March to May). These peaks in prevalence coincided with
increased reports of symptom worsening and higher physician consultation rates. In participants not allergic to
pollen, the autumn and spring peaks were accompanied by a third peak in late December 2012. Very few
participants reported that their symptoms had never improved (4 %) or never worsened (11 %) during the survey
period.
Conclusions: In a survey in France, Italy and Spain, patients with severe HDM-induced respiratory allergies
experienced a complex set of changing, troublesome symptoms throughout the year, with peaks in spring,
autumn and (to a lesser extent) mid-winter.
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Background
House dust mites (HDMs) constitute a major, persistent
source of indoor aeroallergens and constitute the leading
cause of respiratory allergies such as allergic rhinitis
(AR) and allergic asthma. These conditions affect more
than 500 million people worldwide [1, 2]; albeit with sig-
nificant geographical variations (i) in the prevalence and
types of HDMs [1], (ii) domestic levels of HDM allergens
[3] and (iii) levels of sensitization to HDM allergens in
the general population [4, 5]. The link between AR and
asthma is well established, and exposure to HDM aller-
gens early in life is associated with an increased risk of
asthma [6, 7].
Patients consulting an allerggist for HDM allergy tend
to have moderate-to-severe, persistent disease profiles.
In a French, retrospective survey of 1289 patients in
whom allergy immunotherapy (AIT) had been initiated,
Trebuchon et al. [8] reported that 64.9 % had a history
of moderate-to-severe, persistent AR and that 50 % also
suffered from (mainly mild, intermittent) asthma. Fur-
thermore, 62.5 % of the patients were polysensitized and
thus potentially polyallergic (meaning those polysensi-
tized patients with corresponding symptoms related to
those allergens to which they show sIgE). Indeed, 22 %
of the patients had initiated AIT for a second allergen
(usually grass pollen). This profile was seen in both
adults and children [8, 9]. The complexity of clinical
profiles in HDM allergy explains why Worm et al. [10]
found that 88 % of 5751 HDM-allergic patients surveyed
in Germany had consulted a specialist physician rather
than a general practitioner; this contrasted with the pa-
tients with grass pollen allergy only, most of whom were
treated in general practice. The treatment profile for
HDM-allergic patients also differed, with significantly
greater used of topical corticosteroids. The average num-
ber of co-prescriptions was 2.1, and around 9 % of the
patients had received a prescription for AIT [10, 11].
The symptoms of HDM-induced allergy can have a
significant negative impact on a patient’s quality of life
(QoL) [12]. Although the harmful symptoms related to
HDM-induced respiratory allergy are usually always
present to some extent, their intensity varies over time
as domestic HDM populations and allergen levels fall or
rise as a function of weather-related factors or other
changes in the indoor living environment [13, 14]. The
pernicious nature of persistent, HDM-induced allergy
has given rise to the perception among patients [12] that
it is not a “real” disease. For example, sufferers may be-
lieve that pollen allergy is more severe than HDM
allergy-even though this is contradicted by literature
data on clinical profiles and treatments [10, 15] and sim-
ply because pollen only allergic patients are free of
symptoms between two seasons and know what being
“normal” means. Even people with physician-diagnosed
HDM allergy may consider that dust (rather than the
HDMs in dust) is the trigger for their allergic symp-
toms [12].
Despite the availability of symptomatic medications
(generally oral antihistamines and/or nasal corticoste-
roids) [8, 16, 17], HDM-allergic patients may not achieve
adequate disease control. The concept of disease control
goes beyond the mere observation of the frequency and
intensity of allergic symptoms. Although there is no sin-
gle definition of “disease control” in AR, an analogy with
the guidelines on asthma control would prompt one to
consider (i) disease exacerbations (e.g. the need for a
previously unscheduled consultation with a physician, or
the need to take rescue medication), (ii) the presence of
impairments in leisure, sporting, professional and educa-
tional activities, (iii) objective measures of respiratory
function [18]. In the survey described below, the partici-
pants reported non-optimal control at study entry on
the basis of impaired activities and insufficient symptom
relief.
Persistent, HDM-induced respiratory allergies are
further complicated by the superposition of other (some-
times intermittent) allergies, such as those triggered by
grass, tree and weed pollens to which they can be co-
sensitized (and allergic). In a longitudinal, single-centre
study in Sydney (Australia), Downie et al. characterized
changes in the intensity of HDM-induced symptoms
over a one-year period [19]. The typical domestic levels
of HDM allergens in Australia are among the highest re-
corded worldwide; although two- to three-fold seasonal
variations are seen in Sydney, the levels are always well
over the presumed threshold for disease induction
[14, 20, 21]. Downie et al. observed persistent nasal
symptoms throughout the year, with pathologically
high nasal symptom scores for 65 % of the 12-month
study period [19]. Furthermore, increasing nasal
symptom scores were predictive of the use of nasal
medications. In pollen-co-sensitized patients, moderate
seasonal variations in symptom scores had no effect on
QoL and medication use [19]. The value of Downie et al.’s
results are somewhat limited by the small number of
participants (37 completed the study), the single-centre
design and the high presumed domestic levels of HDM
allergens.
Hence, the objective of the present observational, mul-
ticentre survey (performed throughout France, Italy and
Spain) was to assess the self-reported disease profile of a
large number of adult patients with a history of severe,
poorly controlled, physician-diagnosed HDM respiratory
allergy. We focused on poorly controlled patients be-
cause patients with mild-to-moderate, well-controlled
HDM respiratory allergy (i) are less challenging to man-
age and (ii) may more readily display confounding symp-
toms related to allergens other than HDMs. Fortnightly
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telephone interviews were used to gather data on symp-
tom prevalence and intensity, medical consultations, dis-
ease burden, QoL, and medication use over a 12-month
real life period. In the first in a series of companion
articles, we report on the survey’s methodology and the
participants’ demographic characteristics, baseline disease
profile and self-reported changes in symptom intensity
and frequency over the 12-month survey period.
Methods
Survey design and ethical aspects
An observational, Internet- and telephone-based survey
was performed in three Western European countries
(Italy, France and Spain) between March 2012 and July
2013 (Fig. 1). In each country, members of nationwide
patient panels (previously constituted by the study’s
contract research organization (CRO) STETHOS (Sèvres,
France)) were invited to participate in the present survey.
In France, the study was registered with the French Na-
tional Data Protection Commission (Commission Nationale
de l'Informatique et des Libertés, CNIL). In Italy and Spain,
we established that specific ethical and regulatory approval
from independent ethics committees or health authorities
was not required for a non-interventional, anonymous sur-
vey. In all three countries, the contract research
organization complied with (i) the European Pharmaceut-
ical Market Research Association’s guidelines, (ii) national
legislation (notably with declarations to the national data
protection committees and national medical associations)
and (iii) an in-house code of good practice. Panel members
were identified by a unique ID number (known to the CRO
but not to the investigators). The anonymized format of the
study database prevented the direct, nominative identifica-
tion of panel members. The final data were analysed in a
strictly de-identified, aggregated form and therefore could
not be traced back to the respondent. The survey partici-
pants had provided their prior, general consent to partici-
pation in health-related surveys and subsequent
exploitation of the anonymized data. Participants
screened themselves for eligibility (i.e. through self-
reporting) with a short Internet questionnaire (see
below) and were not examined by a physician as part
of the selection process. However, the participants all
had to confirm that they had been diagnosed with
HDM allergy by a physician.
The screening questionnaire
In March and April 2012, potentially eligible people
were screened with a 9-question Internet questionnaire
(Additional file 1: Table S1). This questionnaire and the
other survey questionnaires had been drafted in English,
translated into local languages (Italian, French and Span-
ish) and then translated back into English for validation
[22]. The inclusion criteria were as follows: age 18 or
over; moderate to very severe symptoms of HDM al-
lergy; at least three of the following symptoms: blocked
nose, runny nose, itchy nose, difficulty breathing, cough,
wheezing, sneezing, chest tightening, itchy eyes and tear-
ing; physician-diagnosed HDM allergy (and potentially
other allergies); a positive skin prick test or IgE assay for
HDM allergens; more severe allergic symptoms in
September, October, November or December; no previ-
ous or current AIT; use of at least one antihistamine or
corticosteroid medication; symptoms not sufficiently
controlled by current medication; a moderate to very
strong impact of HDM allergy on QoL. In view of the
descriptive nature of the study, a statistical calculation of
the sample size was not performed and the number of
participants was conditioned by financial and logistic
parameters. The goal was to have approximately 100
participants per country (i.e. 315 in total) at the start of
the 12-month assessment period and 80 per country at
the end of the period). All questionnaire data were an-
onymous. No directly or indirectly nominative informa-
tion was recorded. Included patients were modestly
remunerated for their participation.
The post-inclusion questionnaire
In April and May 2012, all included participants com-
pleted a 28-question post-inclusion questionnaire in an
approximately 35-min telephone interview (Additional
file 2: Table S2). The questionnaire was designed to
probe the participant’s disease history and establish a
baseline so as to compare at the end of the survey, the
behaviour. The collected data included the first symp-
toms of HDM allergy, the types and frequencies of
Fig. 1 Study timeline
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physician consultations, the time interval between the
first symptoms and the first consultation, the presence
of any other physician-diagnosed allergies, the types of
symptoms experienced and their duration, frequency,
seasonality and impact on health and life activities, the
presence of any comorbidities, the use of allergen evic-
tion measures, the types of allergy medications and their
regimens, financial aspects (reimbursement, and costs
linked to changes in the home or work environment)
and, lastly, awareness and opinion of AIT. Again, all
questionnaire data were anonymized. No directly or in-
directly nominative information was recorded.
The fortnightly status questionnaire
From late May 2012 to early July 2013, operators
telephoned each participant every fortnight with a view to
completing a 10-question telephone interview that lasted ap-
proximately 10 min (Additional file 3: Table S3). The ques-
tionnaire, which embedded the5 questions of the ARCT
questionnaire, was used to collect data on the frequency and
intensity of allergy-associated symptoms over the previous
fortnight, the overall symptom severity, improvement, wors-
ening or stability of symptoms, supposed reasons for any
improvement or worsening, medication use, any consulta-
tions with physicians, the occurrence and treatment of co-
morbidities, and the HDM allergy’s impact on life activities
and mood. A total of 28 fortnightly telephone interviews
were scheduled. All questionnaire data were anonymized.
The closing questionnaire
In August 2013, each participant was invited to complete
a 24-question closing questionnaire during an approxi-
mately 20-min telephone interview (Additional file 4:
Table S4). The closing questionnaire addresses the same
topics as the post-inclusion questionnaire and was
intended to identify trends in the management of the par-
ticipant’s HDM allergy or any other major events (moving
house, job changes, changes in the domestic and working
environment, etc.) that may have influenced the disease
signal and disease burden. All questionnaire data were
anonymized.
Data management
A descriptive analysis of the survey data was performed
with SPSS software (version 15.0.1, IBM Corporation,
Armonk, USA). Quantitative parameters are expressed
as the mean, median and range, and qualitative parame-
ters are expressed as the number and the percentage of
the corresponding survey population or subpopulation.
Results and discussion
Screening and post-inclusion data
A total of 22,995 individuals completed the Internet
screening questionnaire and 339 met all the inclusion
criteria. Of these, 313 (n = 114 in Italy, 92 in France and
107 in Spain) were included in the study and completed
the post-inclusion questionnaire. Even though the sam-
ple was not stratified for geographic location, the in-
cluded participants were quite evenly distributed within
each country. For example, 38 % of the 114 participants
from Italy lived in the north of the country, 21 % lived
in the middle regions and 41 % lived in the south. Simi-
larly, participants in Spain were distributed between
coastal locations (67 %) and inland locations (33 %). In
France 59 % lived in the north of the country and 41 %
in the south of the country. It was observed that partici-
pants wanted or needed to talk extensively about their
disease. The post-inclusion questionnaire was meant to
last for 35 min but often lasted longer.
The study population comprised a high proportion of
women (67 % overall: 68 % for Italy, 72 % for France and
61 % for Spain; Table 1). This may have been due to
self-selection bias because women are known to be more
likely than men to participate in epidemiological surveys
[23]. The mean age (Table 1) and age distribution
highlighted the predominance of young adults in the
study population: 18 to 24 years of age: 12 %; 25 to 34:
31 %; 35 to 44: 33 %, 45 to 54: 16 %; 55 to 64: 7 %; over
65: 1 %. This may reflect Internet use in the surveyed
countries, with relatively fewer elderly people online
[24]. Nevertheless, the age distribution appeared to be
similar to that reported by Downie et al. in 2004; the
latter researchers reported a mean (range) age of 33.4
(18–51) in their patients with HDM allergy only and
33.9 (18–64) in their patients with HDM allergy and
pollen allergy [19].
As expected, the majority of participants (61 % in Italy,
and 79 % in France and Spain) reported having another
physician-diagnosed respiratory allergy (mainly due to
grass pollen, followed by weed pollen, pet dander and
tree pollen). In comparison, Downie et al. reported that
(i) 57 % of their study participants were also sensitized
to one or more pollens (ragweed, plantain, timothy grass
or ryegrass), and (ii) some of the remaining 43 % were
sensitized to allergens such as dander and moulds [19].
However, one cannot directly compare the prevalence of
self-reported clinical allergy in the present study with
the results of physician-administered sensitization tests
and examinations (in Downie et al.’s study).
The median time since first symptoms of HDM allergy
was over 13 years in all three countries. Most study par-
ticipants had consulted within a year or two of disease
onset; however, it implied that years of consultations and
treatment offered had been inadequate and that patient’s
needs were unmet and needed to be addressed. Partici-
pants were most likely to consult GPs (over 70 % of par-
ticipants) and allergists (again over 70 % of participants).
Fewer than 20 % of the participants had not consulted a
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Table 1 Characteristics of the survey population, according to the post-inclusion questionnaire
Italy France Spain
Number of participants (n =M/F), % female. 114 (36/78), 68 % 92 (27/65), 72 % 107 (41/66), 61 %
Age: mean, median [range] (years): 37.5, 36 (18–63) 35.8, 36 (18–62) 38.2, 37 (18–68)
Time since first symptoms: mean, median [range] (years): 15.0, 16 (1–45) 17.8, 18 (1–51) 17.3, 13 (1–40)
Time interval between first symptoms and consultation with a
specialist: mean, median [range] (months):
18.9, 4 (0.25–588) 28.4, 6 (0.25–360) 20.3, 11 (0.25–156)
Proportion of patients (%) having consulted the following physicians
(mean number of visits per year):
GP 92 % (3.4) 91 % (3.0) 70 % (3.9)
Allerist 87 % (2.0) 83 % (1.7) 70 % (1.4)
ENT specialist 27 % (2.3) 27 % (2.3) 15 % (1.7)
Dermatologist 24 % (1.6) 20 % (1.7) 8 % (2.6)
Pulmonologist 22 % (1.5) 32 % (1.6) 8 % (6.2)
Paediatrician 14 % (6.8) 9 % (1.0) 7 % (na)
Other 6 % (4.0) 2 % (1.5) 4 % (1.0)
Other self-reported allergies (% of patients):
Grass pollen 79 % 67 % 67 %
Parietaria pollen 57 % 37 % 9 %
Cat dander 49 % 51 % 41 %
Dog dander 31 % 26 % 29 %
Olive pollen 27 % 41 % 35 %
Birch pollen 27 % 44 % 7 %
Moulds 24 % 29 % 35 %
Cypress pollen 21 % 48 % 9 %
None (i.e. HDMs only) 39 % 21 % 21 %
Proportion of patients (%) having consulted the following combinations of physicians:
GP only 17 % 9 % 5 %
Allergist only 18 % 4 % 3 %
GP + allergist 33 % 25 % 31 %
GP + another specialist 7 % 7 % 5 %
GP + two specialists 11 % 29 % 26 %
GP + three or more specialists 4 % 22 % 28 %
Prevalence of co-morbidities (% of patients):
Sinusitis 36 % 53 % 26 %
Otitis 13 % 18 % 9 %
Conjunctivitis 44 % 43 % 33 %
Headache 69 % 62 % 69 %
Time having used symptomatic medications (% of patients):
Less than 2 years 7 % 3 % 3 %
2 to 5 years 35 % 28 % 21 %
6 to 10 years 22 % 39 % 30 %
11 to 20 years 21 % 23 % 27 %
More than 20 years 16 % 7 % 15 %
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specialist physician. The “GP+ allergist” combination
was the most frequent (Table 1). The long disease dur-
ation and the multiple consultations are suggestive of
“doctor-hopping” and unmet patient needs. In Spain,
28 % of the participants had consulted a GP and three
different specialist physicians. Accordingly, over 93 % of
the study participants had been taking symptomatic
medication for more than 2 years (and for more than
20 years in some cases). The mean time since initiating
symptomatic medications was 11.2 years in Italy, 10.1 years
in France and 12.4 in Spain. When participants were
asked which type of physician they consulted when aller-
gic symptoms worsened, the most frequent response was
“a GP” (according to 53 % of the participants in Italy, 51 %
in France and 47 % in Spain). However, the second most
frequent response (except in Italy) was “self-medication”
with over-the-counter products (according to 22 % of the
participants in France, 32 % in Spain and 4 % in Italy).
Italian participants (36 %) were much more likely to
consult an allergist (36 %, compared with 11 % in France
and 12 % in Spain); this may reflect national differences in
healthcare pathways and financial aspects.
The most common comorbidity was headache,
although this was not necessarily related to the HDM
allergy, although allergic rhinitis is a proven-risk factor
for chronic rhinosinusitis [25–27]. The most common
allergy-related comorbidity was conjunctivitis (in 33 to
44 % of the participants). There were some disparities in
terms of disease control when comparing the results of
the Internet-based screening questionnaire and those of
the telephone-based post-inclusion questionnaire. As
mentioned above, one of the inclusion criteria was the
absence of total disease control. However, in response to
the more detailed post-inclusion questionnaire (which
notably included an opportunity to request clarifications
on the meaning of the questions from the person con-
ducting the telephone interview), between 4 and 11 % of
the participants (depending on the country) reported
total disease control and between 43 and 53 % reported
good disease control (Table 1). Hence, only about half of
the “poorly controlled” participants at selection truly
had poor control in the post-inclusion questionnaire.
There were few differences between symptoms (and
indeed between countries) in terms of how bothersome
nose and eye symptoms were judged to be at baseline
(Fig. 2). Over 75 % of participants considered that their
nasal symptoms were extremely or very bothersome.
Chest and skin symptoms (wheezing, cough, chest pain,
trouble breathing in general, trouble breathing when
doing sport and eczema) were less bothersome, with
between 14 and 52 % of the participants reporting them
to be extremely or very bothersome.
In terms of the recalled frequency of symptoms (i.e.
prior to inclusion), most participants were only bothered
during specific periods of the year (53 % in Italy, 36 % in
France and 58 % in Spain. Nevertheless, a sizeable mi-
nority suffered from symptoms of HDM allergy every
day or almost every day of the year (Fig. 3). When those
only bothered during specific periods of the year were
asked to specify the months of the year, spring and
autumn peaks were apparent in all three countries (al-
beit to a lesser extent in France, where the HDM allergy
appeared to be more persistent) (Fig. 4). Although these
data may suffer from recall bias, they mirror the spring
Table 1 Characteristics of the survey population, according to the post-inclusion questionnaire (Continued)
Degree of disease control (% of patients):
Totally controlled 11 % 4 % 10 %
Well controlled 43 % 53 % 48 %
Moderately controlled 42 % 34 % 33 %
Poorly controlled 4 % 7 % 7 %
Not controlled at all 0 % 2 % 3 %
Proportion of patients (%) suffering from symptoms for more than 4 days in a week 70 % 58 % 54 %
Proportion of HDM-only allergic participants (%) with a peak in symptoms. 59 % 63 % 95 %
Proportion of patients (%) taking the following medications:
Antihistamines 38 % 40 % 34 %
Nasal corticoids 7 % 12 % 10 %
Inhaled corticoids 3 % 3 % 9 %
Bronchodilators 7 % 12 % 15 %
Inhaled corticoids + bronchodilator 5 % 7 % 5 %
Oral or topical corticoids 12 % 3 % 4 %
Eye drops 4 % 6 % 4 %
Leukotriene receptor antagonists 2 % 4 % 3 %
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and autumn peaks typically observed in other studies of
HDM allergy in the literature [28, 29]. Furthermore,
these peaks were confirmed in participants with HDM
allergy alone: a peak month of April was specified by 51,
50 and 74 % of intermittently affected participants in
Italy, France and Spain, respectively. Overall, July and
August were least frequently cited as seasonal peaks in
symptoms by participants with HDM allergy alone,
although there were marked differences between the
three countries (8, 33 and 9 % for Italy, France and Spain
in July, respectively). Only 5 % of Spanish participants
stated that there were no specific periods in which
symptoms were more bothersome (vs. 41 % in Italy and
37 % in France). The fact that the majority of “HDM
only” participants recalled seasonal changes suggests that
these peaks were not due to concomitant, intermittent
allergies (e.g., pollen allergies) and that the peaks were
similar irrespective of other associated sensitizations.
According to the post-inclusion questionnaire, antihis-
tamines were the medications most frequently used to
Fig. 2 Impact of symptoms at baseline (according to the post-inclusion questionnaire)
Fig. 3 Frequency of symptoms at baseline (according to the post-inclusion questionnaire)
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relieve allergic symptoms (Table 1), followed by broncho-
dilators, nasal corticosteroids and oral or topical cortico-
steroids. Most participants were taking more than one
medication (80, 85 and 80 % in Italy, France and Spain, re-
spectively). It is noteworthy that 11, 24 and 14 % of the
participants in Italy, France and Spain were taking an anti-
histamine and at least three other medications. The great
majority of French and Spanish participants were aware
that AIT was a potential therapeutic option in HDM al-
lergy (91 and 83 %, respectively). In contrast, only 39 % of
the Italian participants were aware of AIT. However, a
patient’s awareness of AIT did not mean that this treat-
ment option was more likely to be suggested by a phys-
ician: in Spain, AIT had been suggested to 45 % of the
AIT-aware participants. This figure was 54 % in
France and 27 % in Italy.
Changes over a year-long period, as reported by the
fortnightly status interviews
The fortnightly status interviews’ completion rate aver-
aged 75 % and ranged from 29 to 97 %, depending on
the country and the period. The lowest completion rates
a
b
Fig. 4 Self-reported history of seasonal variations in symptoms (according to the post-inclusion questionnaire) by the participants as a whole
(top panel) and by participants allergic to HDMs only (bottom panel)
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were noted in August and September 2012 and June and
July 2013. Overall, the response rates were highest in
Spain and lowest in France.
The fortnightly data on symptom prevalence con-
firmed the post-inclusion data. The time trends for the
four nasal symptoms were similar; the fortnightly preva-
lence of blocked nose, runny nose, sneezing and itchy
nose fell during the summer of 2012, rose in the autumn
(peaking in early October), fell over the winter and rose
again in the spring of 2013 (peaking in late May) (Fig. 5a).
These trends were also confirmed by the reports from
HDM-only participants, albeit with an additional (third)
peak in late December (Fig. 5b) - suggesting that the
spring and autumn peaks observed in the overall survey
population were not due to (for example) tree/grass pollen
in the spring and weed/tree pollen in the autumn. As
mentioned above, Downie et al. noted moderate seasonal
variations in symptom scores in “HDM+pollen-sensitive
patients” but not in HDM-only patients [19]. Even in
Downie et al.’s pollen-sensitive patients, the seasonal vari-
ations in symptom scores had no effect on QoL and medi-
cation use. Downie et al. suggested that this was due to
fluctuating but persistently high allergen levels in the
Sydney indoor environment.
The fortnightly data revealed that chest and skin
symptoms (Fig. 6) were generally less prevalent than
nose and eye symptoms (Fig. 5). The prevalence of chest
and skin symptoms also peaked in autumn and spring,
albeit to a lesser extent than the nose and eye symptoms.
Again, the results for the “HDM-only” participants were
concordant with those for the survey population as a
whole.
The fortnightly data on the prevalence of allergic
symptoms were confirmed by the participants’ judgment
of whether their symptoms had improved, worsened or
stayed the same over the previous fortnight (Additional
file 5: Figure S1). The highest proportions of participants
with worsened symptoms were noted between early
a
b
Fig. 5 a Fortnightly status reports: the percentage of surveyed participants experiencing nasal symptoms (all patients, including those with
concomitant allergies). b Fortnightly status reports: the percentage of surveyed participants experiencing nasal symptoms (“HDM only participants”, i.e.
those with no concomitant allergies)
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September and late November 2012, and then again be-
tween late March and early May 2013. Very few partici-
pants reported that their symptoms had never improved
(4 % overall; 2, 2 and 7 % in Italy, France and Spain, re-
spectively) or never worsened (11 % overall; 12, 6 and
13 % in Italy, France and Spain, respectively) at any time
during the study period. Again, the reports from HDM-
only participants confirmed the overall picture, with the
greatest proportion of “worsening” reported between
early October and early December 2012 and then again
between late March and early May 2013. A substantial
proportion of participants (21 to 53 %, depending on the
time of year) did not have an explanation (such as a
change in medication use, a change in the environment
or weather, greater exposure to dust, etc.) for the wors-
ening or improvement in their symptoms, illustrating
the complexity of the symptom profile in this context.
Lastly, the autumn and spring peaks of symptom preva-
lence and worsening appeared to be associated with
more frequent consultation of a physician (Fig. 7 and
Additional file 6: Figure S2). In 2012, between 9 and
24 % of the participants had consulted a physician in the
previous fortnight; unsurprisingly, the holiday month of
August had the lowest consultation rates in 2012. In
2013, the peak in consultations (April and May) coin-
cided with high rates of worsening.
In future research, it would be interesting to look for
demographic and/or clinical risk factors associated with
improvement or worsening. These fluctuating symptoms
are likely to have had an impact on the participants’
degree of disease control, burden of disease (including
financial factors and the need for medication), QoL (in-
cluding sleep quality) and perception of disease. The
fortnightly status interviews collected extensive data on
these subjects, which will be described in a future com-
panion article. By way of an example, the symptoms of
HDM allergy markedly altered QoL between 2 and 4 days
per fortnight on average, and led to time off work in up
to 11 % of participants (although this proportion varied
markedly over the 12-month study period)).
a
b
Fig. 6 a Fortnightly status reports: the percentage of surveyed patients experiencing chest and eczema symptoms (all three countries pooled, all
patients - including those with concomitant allergies). b the percentage of surveyed patients experiencing chest and eczema symptoms, according to
fortnightly status reports during the survey period (all three countries pooled, patients with no concomitant allergies, i.e. HDM allergy only)
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Changes over the study period, as reported in the final
questionnaire
A total of 214 participants (including 63 HDM-only par-
ticipants) completed the final questionnaire (n = 72 in
Italy, 70 in France and 72 in Spain). Compared with
12 months previously, 63 % of the respondents stated
that their general condition was much the same (improve-
ment: 32 %; worsening: 5 %). For HDM-only participants,
these proportions were 73, 22 and 5 %. Both improve-
ments and worsening were primarily attributed to changes
in treatment and in the weather. 41 % of the respondents
stated that the symptom of blocked nose was still very or
extremely bothersome; this value was 36 % for sneezing,
34 % for a runny nose and 20 % for difficulty breathing.
Strikingly, over 65 % of the respondents remembered their
answers on this topic in the post-inclusion questionnaire
completed 12 months previously, suggesting that their
judgements of bothersome symptoms were reliable. When
participants were asked to rate (on a 0 to 10 scale) the
extent to which their symptoms were controlled by their
medications, the mean score was 6.9 in Italy, 7.0 in France
and 7.3 in Spain. Fewer than 6 % of participants reported
completely uncontrolled disease. Use of three of more med-
ications was not uncommon (28, 33 and 17 % of the re-
spondents in Italy, France and Spain, respectively). Very
few (n = 18, 8.4 %) participants had initiated AIT during the
study (4, 1 and 13 in Italy, France and Spain, respectively).
The present study had several limitations, most of
which apply to all self-reported, observational, Internet-
or phone-based surveys. Fortnightly phone interviews
may have induced a recall effect, and the closing
questionnaire required participants to recall events and
opinions up to 12 months previously. The data were
self-reported over the Internet, which may have intro-
duced bias. For practical reasons, self-reporting is
frequent in “real-life” epidemiological surveys and (by
definition) obligatory in online questionnaires that probe
patient-reported outcomes (PROs) such as functional
impairments and quality of life. However, self-reporting
can introduce several different types of bias (for a re-
view, see [30]). Firstly, subjective self-reporting is based
on an individual’s subjective memories of his/her
a
b
Fig. 7 a symptom intensity and consultation with a physician, according to fortnightly status reports during the survey period (all three countries
pooled and all patients, including those with concomitant allergies). b symptom intensity and consultation with a physician, according to fortnightly
status reports during the survey period (all three countries pooled but only patients with no concomitant allergies, i.e. HDM allergy only)
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medical history and life events. The individual may
therefore remember some events selectively, with un-
pleasant events and periods more likely to be remem-
bered more clearly than pleasant ones. In addition,
individual participant’s perception of risk can theoretic-
ally affect the validity of self-reported symptoms and
perceived exposure is often an independent determinant
of health outcome. Likewise, the recall period has an in-
fluence on responses; more recent events will be remem-
bered more accurately than less recent ones. Secondly,
social factors can influence recall and reporting; answers
that are less socially acceptable or may be subject to stigma
are less likely to be reported. However, it appears that the
advantages of using PROs are currently outweighing the
drawbacks, since the proportion of clinical trials at Clini-
calTrials.gov reporting at least one PRO increased from
14 % prior to 2007 to 27 % between 2007 and 2013 [31].
This Internet-based survey was subject to selection
bias. The present survey population was not representa-
tive of HDM-allergic people in general or of HDM-allergic
patients consulting an allergist. For example, females were
over-represented in the present survey (accounting for
67 % of the population) with regard to a typical patient
population (e.g. 46.1 % in Trébuchon et al.’s study of
French HDM-allergic patients consulting an allergist [8]).
Furthermore, the present survey was subject to age bias.
For example, data from the latest French national census
(http://www.insee.fr/fr/themes/tableau.asp?reg_id=0&ref_
id=NATnon02150) show that the 25 to 34, 35 to 44, 45
to 54 and 55 to 64 year age classes comprised respectively
12.1, 12.9, 13.5 and 12.5 % of the total population. In the
present survey, these proportions were 31, 33, 16 and 7 %,
respectively. Unsurprisingly, the Internet-based nature of
our survey meant that young adults were markedly over-
represented and older adults were underrepresented. This
corresponds to coverage bias, since older adults are less
likely to be Internet users [24]. The remuneration for
study participation may also have introduced a socioeco-
nomic status and age selection bias. Furthermore, the par-
ticipants’ self-assessments of symptom severity and impact
on QoL were not recorded with validated tools. The study
questionnaires were custom tools and had not been exten-
sively tested or psychometrically validated prior to the
present study. In contrast to Downie et al.’s study, the
clinical inclusion criteria were not verified by a physician,
and interviews were not performed by physicians or other
medical staff (although the majority of Downie et al.’s data
also came from fortnightly phone interviews). Further-
more, we did not include a control group. In fact, Downie
et al. monitored non-rhinitic subjects in order to establish
the normal range for nasal symptom scores (defined as
two standard deviations of the mean) [19]. Next, the ab-
sence of physician-validated clinical data meant that we
did not perform any statistical analyses (notably
comparisons of one country with another, and analyses of
time trends). The fortnightly status interviews suffered
from a variable completion rate, especially during holiday
periods in the summer and at the end of the year.
The study collected relatively little data on symptoms
potentially associated with asthma. However, the fact that
between 7 and 15 % of the participants had taken bron-
chodilators suggests that asthma was present. For cost
reasons, HDM allergen levels were not measured in
homes, although the value of this measurement is subject
to debate [32–35]. Similarly, pollen counts across the
many centres were not monitored and HDM avoidance
measures were not uniform at baseline and differed from
country to country and patient to patient. By comparison,
Downie et al. was easily able to obtain pollen count data
for Sydney [19].
Conversely, our study had some notable strengths: its
international, multicentre design, the relatively large num-
ber of participants (at least when compared with the 37 in
Downie et al.’s study [19]), the detailed post-inclusion and
closing questionnaires, and the high frequency of follow-
up interviews and detailed on participants with uncon-
trolled disease.
Conclusions
Patients in France, Italy and Spain with severe HDM-
induced allergic rhinitis and asthma experienced trouble-
some symptoms throughout the year, with peaks in spring,
early autumn and (in HDM-only participants) late winter.
A substantial proportion of participants did not have an
explanation for the worsening or improvement in their
symptoms-illustrating the complexity, variability and the
hidden aspect of the disease in this context. At the end of
the survey period, nasal symptoms were stated to be very
or extremely bothersome by over 40 % of respondents,
suggesting the persistence of unmet needs.
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